计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| A414042-1mg |
1mg |
现货 ![]() |
| |
| A414042-5mg |
5mg |
现货 ![]() |
| |
| A414042-10mg |
10mg |
现货 ![]() |
| |
| A414042-25mg |
25mg |
现货 ![]() |
| |
| A414042-50mg |
50mg |
期货 ![]() |
|
| 英文别名 | JQ1-VHL |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | ARV-771 |
| 生化机理 | ARV-771 是一种新型 BET-PROTAC(蛋白水解靶向嵌合体),是一种强效泛(溴结构域和末端外)BET 降解剂,对 BRD2(1)、BRD2(2)、BRD3(1)、BRD3(2)、BRD4(1)和 BRD4(2) 的 Kd 分别为 34 nM、4.7 nM、8.3 nM、7.6 nM、9.6 nM 和 7.6 nM。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 含 2 个溴odomain 的抑制剂;含 3 个溴odomain 的抑制剂;含 4 个溴odomain 的抑制剂 |
| 产品介绍 |
Information ARV-771 is a potent pan-(bromodomain and extra-terminal)BET degrader, a novel BET-PROTAC(proteolysis-targeting chimera) with Kd of 34 nM, 4.7 nM, 8.3 nM, 7.6 nM, 9.6 nM, and 7.6 nM for BRD2(1), BRD2(2), BRD3(1), BRD3(2), BRD4(1), and BRD4(2), respectively. Targets BRD2-BD2 (Cell-free assay); BRD3-BD2 (Cell-free assay); BRD4-BD2 (Cell-free assay); BRD3-BD1 (Cell-free assay); BRD4-BD1 (Cell-free assay) 32850,4.7 nM(Kd); 7.6 nM(Kd); 7.6 nM(Kd); 8.3 nM(Kd); 9.6 nM(Kd) In vitro ARV-771 is a potent small-molecule pan-BET degrader based on proteolysis-targeting chimera (PROTAC) technology, demonstrates dramatically improved efficacy in cellular models of CRPC as compared with BET inhibition. ARV-771 treatment of CRPC cells results in apoptosis. In vivo ARV-771 induces degradation in vivo. ARV-771 results in suppression of both AR signaling and AR levels and leads to tumor regression in a CRPC mouse xenograft model. Cell Research(from reference) Cell lines:22Rv1 cells, VCaP cells, LnCaP95 cells Concentrations:1-300 nM Incubation Time:24 h, 72 h |
| 纯度 | ≥98% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | (2S,4R)-1-[(2S)-2-[[2-[3-[2-[[2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]acetyl]amino]ethoxy]propoxy]acetyl]amino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide |
| INCHI | 1S/C49H60ClN9O7S2/c1-27-30(4)68-48-41(27)42(33-14-16-35(50)17-15-33)54-37(45-57-56-31(5)59(45)48)23-39(61)51-18-21-65-19-9-20-66-25-40(62)55-44(49(6,7)8)47(64)58-24-36(60)22-38(58)46(63)53-28(2)32-10-12-34(13-11-32)43-29(3)52-26-67-43/h10-17,26,28,36-38,44,60H,9,18-25H2,1-8H3,(H,51,61)(H,53,63)(H,55,62)/t28-,36+,37-,38-,44+/m0/s1 |
| InChi Key | PQOGZKGXGLHDGS-QQRWPDCKSA-N |
| Smiles | CC1=C(SC2=C1C(=NC(C3=NN=C(N32)C)CC(=O)NCCOCCCOCC(=O)NC(C(=O)N4CC(CC4C(=O)NC(C)C5=CC=C(C=C5)C6=C(N=CS6)C)O)C(C)(C)C)C7=CC=C(C=C7)Cl)C |
| Isomeric SMILES | CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)NCCOCCCOCC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@H](C)C5=CC=C(C=C5)C6=C(N=CS6)C)O)C(C)(C)C)C7=CC=C(C=C7)Cl)C |
| 分子量 | 986.64 |
| Reaxy-Rn | 56712042 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=56712042&ln= |
| 溶解性 | Solubility (25°C) In vitro DMSO: 100 mg/mL (101.35 mM); Ethanol: 100 mg/mL (101.35 mM); Water: Insoluble; |
|---|---|
| 分子量 | 986.600 g/mol |
| XLogP3 | 5.900 |
| 氢键供体数Hydrogen Bond Donor Count | 4 |
| 氢键受体数Hydrogen Bond Acceptor Count | 13 |
| 可旋转键计数Rotatable Bond Count | 19 |
| 精确质量Exact Mass | 985.375 Da |
| 单同位素质量Monoisotopic Mass | 985.375 Da |
| 拓扑极表面积Topological Polar Surface Area | 259.000 Ų |
| 重原子数Heavy Atom Count | 68 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 1750.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 5 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. Raina K, Lu J, Qian Y, Altieri M, Gordon D, Rossi AM, Wang J, Chen X, Dong H, Siu K et al.. (2016) PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.. Proc Natl Acad Sci USA, 113 (26): (7124-9). [PMID:27274052] |